These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. An interview with Martin Rosenberg, Ph.D. Interviewed by Vicki Glaser. Rosenberg M Assay Drug Dev Technol; 2009 Dec; 7(6):537-43. PubMed ID: 20035618 [No Abstract] [Full Text] [Related]
8. Masters of their universe. Osborne R; DeFrancesco L Nat Biotechnol; 2009 Jun; 27(6):528-30. PubMed ID: 19513053 [TBL] [Abstract][Full Text] [Related]
9. Perspectives: biotechnology in Czech Republic, the past and the future. Damborský J; Prokop Z; Kostka M Biotechnol J; 2006 May; 1(5):487-90. PubMed ID: 16892283 [No Abstract] [Full Text] [Related]
10. "Extraordinary Measures": Arrowsmith for the NASDAQ era. Weissmann G FASEB J; 2010 Apr; 24(4):963-7. PubMed ID: 20356907 [No Abstract] [Full Text] [Related]
11. Profile: Thomas Lönngren. Louët S Nat Biotechnol; 2004 Nov; 22(11):1341. PubMed ID: 15529143 [No Abstract] [Full Text] [Related]
12. Mexico, the father of the pill and the race for cortisone. Renneberg R Biotechnol J; 2008 Apr; 3(4):449-51. PubMed ID: 18412173 [No Abstract] [Full Text] [Related]
17. Interview with Thomas P. Monath, M.D. Interview by Vicki Glaser. Monath TP Vector Borne Zoonotic Dis; 2005; 5(3):300-4. PubMed ID: 16187902 [No Abstract] [Full Text] [Related]
18. Venter's departure sees Celera seek therapies. Dennis C Nature; 2002 Jan; 415(6871):461. PubMed ID: 11823816 [No Abstract] [Full Text] [Related]
19. A brief history of novel drug discovery technologies. Gershell LJ; Atkins JH Nat Rev Drug Discov; 2003 Apr; 2(4):321-7. PubMed ID: 12669031 [TBL] [Abstract][Full Text] [Related]
20. Ten years on--the European perspective. Biotech company founders talk about what made their companies tick. Collingham DP Biotechnology (N Y); 1993 Mar; 11(3):S44-6. PubMed ID: 7763435 [No Abstract] [Full Text] [Related] [Next] [New Search]